Myriad Genetics Inc. (MYGN)
Nasdaq · In Vitro & In Vivo Diagnostic Substances · Manufacturing · CIK 899923 · fiscal year ends in Dec
Closing price $6.66 on 29 Oct 2026; 52-week range $2.86 to $8.18.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $806.6M
- Revenue growth
- -3.2%
- Net income, last twelve months
- -$112.6M
- Earnings per share
- -$1.19
- Gross margin
- 68.8%
- Operating margin
- -12.2%
- Net margin
- -14.0%
- Return on equity
- -37.1%
- Market value
- $636.7M
- Cash
- $115.2M
- Debt
- $120.7M
- Debt to equity
- 0.40
- Shares outstanding
- 95.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $824.5M | -$387.2M | -$365.9M | -$3.95 | – | 10-K filed 24 Feb 2026 |
| FY2024 | 31 Dec 2024 | $837.6M | -$123.5M | -$127.3M | -$1.41 | – | 10-K filed 28 Feb 2025 |
| FY2023 | 31 Dec 2023 | $753.2M | -$257.4M | -$263.3M | -$3.18 | – | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $678.4M | -$140.6M | -$112.0M | -$1.39 | -$151.6M | 10-K filed 1 Mar 2023 |
| FY2021 | 31 Dec 2021 | $690.6M | -$190.5M | -$27.2M | -$0.35 | $600.0K | 10-K filed 25 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $190.7M | -$43.2M | -$0.46 |
| Q1 FY2026 | 31 Mar 2026 | $200.4M | -$34.1M | -$0.36 |
| Q4 FY2025 | 31 Dec 2025 | $209.8M | -$7.9M | -$0.08 |
| Q3 FY2025 | 30 Sep 2025 | $205.7M | -$27.4M | -$0.29 |
| Q2 FY2025 | 30 Jun 2025 | $213.1M | -$330.5M | -$3.57 |
| Q1 FY2025 | 31 Mar 2025 | $195.9M | -$100.0K | $0.00 |
| Q4 FY2024 | 31 Dec 2024 | $210.6M | -$42.5M | -$0.47 |
| Q3 FY2024 | 30 Sep 2024 | $213.3M | -$22.1M | -$0.24 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Hereditary Cancer | $372.4M | 45.2% |
| Prenatal | $186.3M | 22.6% |
| Mental Health | $144.1M | 17.5% |
| Tumor Profiling | $121.7M | 14.8% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $768.0M | 93.1% |
| RoW | $56.5M | 6.9% |
Company events
The newest 8-K filings of 251 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 20 Oct 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 9 Oct 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 16 Sep 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 30 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Jun 2026 | 8-K | Leadership change | 5.02 |
| 4 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 5 May 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K/A | Results | 2.02, 9.01 |
| 3 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 7 Oct 2025 | 8-K | Leadership change | 5.02, 9.01 |
Every filing
The newest filings with the SEC of 539 held.
| Filed | Form | Period |
|---|---|---|
| 20 Oct 2026 | 8-K | 19 Oct 2026 |
| 9 Oct 2026 | 8-K | 6 Oct 2026 |
| 16 Sep 2026 | 8-K | 15 Sep 2026 |
| 31 Jul 2026 | 10-Q | 30 Jun 2026 |
| 30 Jul 2026 | 8-K | 30 Jul 2026 |
| 23 Jun 2026 | 8-K | 17 Jun 2026 |
| 4 Jun 2026 | 8-K | 4 Jun 2026 |
| 4 Jun 2026 | S-8 | – |
| 4 Jun 2026 | S-8 | – |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 5 May 2026 | 8-K | 5 May 2026 |
| 14 Apr 2026 | ARS | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 8 Jun 2026 | Kumar Rashmi, Director | Sale under a trading plan | 15,000 | $4.46 | $66.8K | 171,889 | 9 Jun 2026 |
| 14 May 2026 | Bisaro Paul, Director | Purchase | 7,500 | $3.69 | $27.6K | 97,441 | 14 May 2026 |
| 9 Mar 2026 | Raha Samraat S., President and CEO | Purchase | 40,000 | $5.00 | $199.8K | 493,104 | 9 Mar 2026 |
| 27 Feb 2026 | Phanstiel S. Louise, Director | Purchase | 48,000 | $4.66 | $223.7K | 281,951 | 27 Feb 2026 |
| 26 Feb 2026 | Phanstiel S. Louise, Director | Purchase | 50,407 | $4.80 | $242.1K | 233,951 | 27 Feb 2026 |
| 25 Feb 2026 | Phanstiel S. Louise, Director | Purchase | 6,100 | $4.74 | $28.9K | 183,544 | 27 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 8 Jun 2026 | Kumar Rashmi, Director | 15,000 | $68.8K | 8 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock Portfolio Management LLC | 13G amended | 8.6% | 8.2M |
| 4 Sep 2026 | BlackRock Portfolio Management LLC | 13G | 10.4% | 9.9M |
| 14 Aug 2026 | GLENVIEW CAPITAL MANAGEMENT, LLC | 13G amended | 0% | 0 |
| 14 Aug 2026 | Vestal Point Capital, LP | 13G | 6.1% | 5.7M |
| 7 Aug 2026 | STATE STREET CORPORATION | 13G | 5.3% | 5.0M |
| 12 May 2026 | STATE STREET CORPORATION | 13G | 4.7% | 4.4M |
| 7 Apr 2026 | BlackRock, Inc. | 13G amended | 8.5% | 8.0M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 11 Feb 2026 | Integrated Core Strategies (US) LLC | 13G amended | 7.2% | 6.7M |
| 9 Feb 2026 | STATE STREET CORPORATION | 13G | 6.4% | 6.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 9.3M | +8.44% | 5.32 |
| 30 Sep 2026 | 8.5M | -8.55% | 4.25 |
| 15 Sep 2026 | 9.3M | +19.14% | 4.27 |
| 31 Aug 2026 | 7.8M | +2.1% | 5 |
| 14 Aug 2026 | 7.7M | -9.57% | 2.97 |
| 31 Jul 2026 | 8.5M | +6.07% | 3.91 |
| 15 Jul 2026 | 8.0M | -6.47% | 7.32 |
| 30 Jun 2026 | 8.6M | -1.01% | 4.37 |
Funds that hold it
From each fund's latest Form 13F.
244 funds held it at 30 Jun 2026: 115 added and 58 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 10,890,440 | $62.2M | +2,000,796 |
| Millennium Management LLC | 6,620,372 | $37.8M | -48,445 |
| Vestal Point Capital, LP | 5,735,000 | $32.7M | +4,087,000 |
| State Street Corp. | 4,985,060 | $28.5M | +561,033 |
| D. E. Shaw & Co., Inc. | 4,582,083 | $26.2M | +82,359 |
| Vanguard Capital Management LLC | 4,081,376 | $23.3M | +156,851 |
| Acadian Asset Management LLC | 3,126,973 | $17.8M | +818,384 |
| Vanguard Portfolio Management LLC | 3,079,670 | $17.6M | +497,439 |
| AQR Capital Management LLC | 2,766,689 | $15.8M | +854,393 |
| Morgan Stanley | 2,481,104 | $14.2M | -687,638 |
Peers
Companies in the same industry.
- IDEXX Laboratories Inc. (IDXX): revenue $4.6B, market value $45.4B
- Lantheus Holdings, Inc. (LNTH): revenue $1.6B, market value $6.5B
- Neogen Corp. (NEOG): revenue $884.0M, market value $2.7B
- Celldex Therapeutics, Inc. (CLDX): revenue $157.0K, market value $2.3B
- Intellia Therapeutics, Inc. (NTLA): revenue $59.5M, market value $1.9B
- QuidelOrtho Corp. (QDEL): revenue $2.7B, market value $939.8M